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Conclusions. Mesangial RBC fragments are indicative of mi-Microangiopathic injury and augmented PAI-1 in human dia-
crovascular injury and mesangiolysis in DN and are associatedbetic nephropathy.
with worse proteinuria, and possible worse prognosis. PossibleBackground. Microvascular injury and mesangial dysfunc-
pathogenic mechanisms involve the fibrinolytic/proteolytic sys-tion contribute to the pathogenesis of diabetic glomerulosclero-
tem and locally activated PAI-1.sis. We investigated the extent of microvascular injury charac-
terized by fragmented red blood cells (RBCs) in the mesangium
of glomeruli in diabetic nephropathy, and its clinicopathologic
significance. We also investigated the possible contributions Diabetic nephropathy (DN) is the most common causeof plasminogen activator inhibitor-1 (PAI-1), which has been
of chronic renal failure in the United States [1]. Numer-implicated in thrombosis and sclerosis, and the novel steroid
ous factors have been implicated in the pathogenesis ofreceptor superfamily member, peroxisome proliferator-acti-
vated receptor (PPAR), implicated in monocyte-foamy mac- DN including hyperfiltration, hypertension, poor meta-
rophage transformation in atherosclerosis and improved insu- bolic control of diabetes and growth factors [2]. Mesan-
lin responsiveness in diabetes. gial matrix accumulation is a key lesion in DN. Mesangial
Methods. Sixty-four diabetic nephropathy (DN) cases in our
extracellular matrix (ECM) accumulation results whenrenal biopsy files at VUMC, diagnosed between 1997 and 1999,
ECM synthesis exceeds its degradation. Dysregulatedwere reviewed. Patients were classified based on the presence
or absence of fragmented RBCs in the mesangium (M, M). ECM metabolism thus is the key to ECM accumulation,
PAI-1 and PPAR immunostaining was performed with double the hallmark of glomerulosclerosis.
staining for the macrophage marker CD68. Mesangiolysis followed by augmented ECM synthesis
Results. M lesions were present in 21.9% of cases, and in is thought to underlie the lamellated Kimmelstiel-Wilsonpositive cases, involved on average 10.2  2.1% of glomeruli.
nodules characteristic of DN. However, intraglomerularM patients were 40- to 78-years-old (mean  SD, 60.4 9.8),
RBC fragmentation, a lesion associated with mesangio-the female/male ratio was 2.5, and the white/black ratio was
6. In M, the patients’ ages ranged from 29 to 81 years (57.6 lysis and microvascular injury in thrombotic microan-
13.3, P  NS vs. M), the female/male ratio was 0.5 (P  0.05 giopathy, has not been described in DN. We therefore
vs. M), and the white/black ratio was 2.3 (P  0.1 vs. M). investigated the presence and extent of fragmented redMean 24-hour urine protein in M was 9.9  13.6 g/24 h,
blood cells in glomeruli in patients with DN as a possibleversus 4.0  2.8 g/24 h in M (P  0.05). The fragmented
marker of increased microvascular injury.RBCs in M cases localized exclusively within Kimmelstiel-
Wilson nodules. PAI-1 and PPAR immunostaining was in- We investigated the possible contributions to this mi-
creased in areas of sclerosis in arteries and glomeruli, with crovascular injury by local plasminogen activator inhibi-
expression of both in glomerular mesangial, parietal and vis- tor-1 (PAI-1). PAI-1 inhibits not only fibrinolysis, but
ceral epithelial cells. Infiltrating macrophages in glomeruli were
also proteolysis, by inhibiting activation of plasminogenPPAR negative, contrasting positivity in macrophages in con-
activators (PA). Plasmin can cleave most ECM proteinstrol cases of carotid artery plaque and in renal interstitial mac-
rophages. The Kimmelstiel-Wilson nodules in M patients [3–6], and both tissue type (t-PA) and urokinase plasmin-
showed increased PAI-1 staining. ogen activators (u-PA) play important roles in vascular
remodeling, angiogenesis and tumor metastasis [6]. Tis-
sue type-PA primarily effects fibrinolysis, whereas u-PAKey words: diabetic nephropathy, microvascular injury, mesangiolysis,
has less affinity for fibrin but avidly degrades matrix [6].plasminogen activator inhibitor-1, peroxisome proliferator-activated
receptor-, macrophages. PAI-1 expression is normally present in very low levels in
the kidney, and is expressed in vitro in many cells, includ-Received for publication May 4, 2001
ing endothelial and visceral epithelial cells [4, 6]. PAI-1and in revised form February 4, 2002
Accepted for publication February 5, 2002 is increased in settings of vascular injury, whether throm-
botic or fibrotic [4, 7, 8]. Increased PAI-1 levels, whether 2002 by the International Society of Nephrology
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due to the functional 4G/4G polymorphism of the PAI-1 1999 were reviewed. Biopsies containing at least five
gene promoter, or for other causes, are associated with glomeruli by light microscopy, with immunofluorescence
cardiovascular disease [9]. Diabetic patients with com- and/or electron microscopy to rule out other concurrent
pound polymorphisms for both the PAI-1 4G and the renal disease, were included. Electron microscopy was
ACE D alleles, which increase renin angiotensin system done in 61 cases, 49 of these M and 12 M (see below).
activity, had increased macrovascular disease [10]. PAI-1 Sixty-four cases met these inclusion criteria. Age, gender,
plasma levels are increased in diabetes [11, 12], and we race, level of serum creatinine and 24-hour urine protein
therefore postulated that local increase in PAI-1 could were determined from the clinical record, and follow-up
be related to locally more severe injury in diabetic ne- was obtained by chart review or contacting the referring
phropathy. nephrologist.
We also examined the expression of the novel steroid
Histological assessmentreceptor superfamily member, peroxisome proliferator-
activated receptor- (PPAR), implicated in monocyte- All slides were reviewed and cases were classified based
foamy macrophage transformation in atherosclerosis and on the presence or absence of fragmented red blood cells
improved insulin responsiveness in diabetes [13]. Follow- in the mesangium (M, M). For most cases, nine glass
ing activation, PPAR heterodimerizes with retinoic X slides, each with multiple levels of sections, were re-
receptor (RXR) and binds to peroxisome proliferator viewed. For seven cases, only four slides, each with multi-
response elements (PPREs) in the promoter region of ple levels, were available for review. Extent of nodular
target genes, thereby regulating their transcription [14]. glomerulosclerosis was assessed by the percent of glo-
PPAR plays a major role in the regulation of adipocyte meruli containing Kimmelstiel-Wilson nodules, assessed
differentiation, the expression of adipocyte-specific genes on the single section containing the most glomeruli. Ex-
and of key regulatory genes involved in carbohydrate and tent of lamellation of the Kimmelstiel-Wilson nodules
lipid metabolism [13]. One of the earliest steps in the was assessed by percent of glomeruli with mesangial nod-
formation of atherosclerotic lesions is the conversion of ules that showed a multi-laminated appearance viewed
macrophages to cholesterol-engorged foam cells. The for- with Jones’ silver stain.
mation of foam cells is characterized by dramatic changes Normal control samples were obtained from five adult
in lipid metabolism, including increased expression of patients using uninvolved portions of surgically removed
scavenger receptors and uptake of oxidized low-density kidneys diagnosed with malignancies. These patients had
lipoprotein (LDL). In vitro, PPAR promoted monocyte no urinary abnormality, and histopathological examina-
to foam cell transformation and uptake of oxidized LDL tion of the control tissue excluded any glomerular disease.
through transcriptional induction of scavenger receptors
CD36 [15, 16]. Further, in vivo PPAR was expressed at Immunohistochemical studies
high levels in foam cells of human atherosclerosis lesions
Formalin-fixed paraffin-embedded tissue was avail-[17]. These observations suggested PPAR has potential
able in 47 of 64 cases for immunostaining for PAI-1 andadverse effects in atherosclerosis.
51 of 64 cases for double staining for PPAR and macro-Peroxisome proliferator-activated receptor- activa-
phages. Immunohistochemical staining was performed us-tion also can regulate other mediators of vascular lesions,
ing the avidin-biotin-peroxidase technique with the fol-such as PAI-1. Variable response of PAI-1 to PPAR ac-
lowing antibodies: monoclonal antibody to human PAI-1tivation was observed in in vitro studies in endothelial cells
(1:25; American Diagnostica, Greenwich, CT, USA) and[18, 19]. Recent studies in mesangial cells in culture showed
monoclonal antibody to mouse PPAR (1:10; Santa CruzPAI-1 mRNA induction was decreased by PPAR ago-
Biotechnology, Santa Cruz, CA, USA). Double staining fornist [20]. In vivo, beneficial effects of PPAR were dem-
PPAR and macrophages was performed using mono-onstrated in diabetic nephropathy and in the WHHL
clonal mouse anti-human macrophage antibody to CD68rabbit model of atherosclerosis [21, 22]. We recently
(1:100; Dako, Carpinteria, CA, USA) with alkaline phos-demonstrated that PPAR agonist was protective even
phatase-streptavidin method following PPAR staining.in a nondiabetic model of progressive glomerulosclerosis
Briefly, 4 m paraffin sections were deparaffinizedin the rat [23]. This effect was associated with decreased
in xylene, rehydrated in graded ethanols, and quenchedPAI-1. Therefore, we also examined the expression of
in 3% H2O2/methanol solution for 10 minutes to blockPPAR in diabetic nephropathy and its possible interre-
endogenous peroxidase. For PPAR, sections were thenlationship with macrophage-induced lesions and PAI-1.
pre-treated with antigen retrieval by microwaving for
20 minutes in a 0.01 mol/L citrate buffer (pH 6), fol-
METHODS lowed by avidin/biotin block (InnoGenex, San Ramon,
Patient selection CA, USA). Both PAI-1 and PPAR sections were then
treated with proteinaceous block for endogenous anti-All cases of diabetic nephropathy in native kidney bi-
opsies diagnosed in our laboratory between 1997 and genic sites (Powerblock; InnoGenex) for 30 minutes at
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Table 1. Patient and biopsy characteristicsroom temperature. Either PPAR or PAI-1 antibody was
then applied to the sections, which were incubated over- M group M group
night at 4C. Sections were washed 	3 in phosphate- N 50 14
Mean age years 57.613.3 60.49.8buffered saline (PBS) triton, and sequentially incubated
F/M ratio 0.5 2.5cwith rabbit anti-mouse IgG (1:100 for 40 min; Dako, CA,
Indications for renal biopsy
USA) and PPAR swine anti-rabbit IgG (1:50 for 30 Increased serum creatinine, proteinuria 22 2
Nephrotic proteinuria 6 8min; Dako) and finally developed with diaminobenzidine
Hematuria and proteinuria and/or(DAB) as chromagen. Double staining with monoclonal
increased serum creatinine 12 0
antibody CD68 (1:100 for 90 min; Dako) for identifica- Unusual time coursea 6 4
Other laboratory abnormalitiesb 4 0tion of macrophages also was performed. Sections were
W/B ratio 2.3 6.0rinsed 	3 and sequentially incubated with secondary
Proteinuria g/24 h 4.02.8 9.913.6c
biotinylated goat anti-mouse IgG (InnoGenex) for 30 Serum creatinine mg/dL 3.42.2 2.71.7
Clinical evidence of hemolysis 2/15 3/5cminutes and alkaline phosphatase-streptavidin conjugate
Extent of nodular glomerulosclerosis % 30.027.0 63.328.7c(InnoGenex) for 30 minutes. Finally, sections were de-
Lamellation of Kimmelstiel-Wilson
veloped with Sigma fast red TR/Naphtol AS-MX for five nodules 21/29 14/14c
minutes, counterstained with hematoxylin and cover- a The known duration of diabetes was short (5 years, in 5/6 of these M and
3/4 of these M patients) or long (20 years, 1/6 of these M and 1/4 of theseslipped with aqueous based permanent mounting media
M patients) relative to onset of renal dysfunction(Innovex-Biosciences, Richmond, CA, USA). Negative b One patient each had positive ANA, p-ANCA, hepatitis C or serum mono-
clonal protein. There was, by entry criteria, no evidence of disease related tocontrol slides treated with nonspecific antisera instead
these abnormalities in the biopsies.of primary antibody showed no staining. Positive control c P  0.05 vs. M group
samples for PAI-1 were obtained from three adult pa-
tients with hypertensive nephropathy. Human carotid
artery plaques were used as positive control for double
staining for CD68 and PPAR. Concurrent staining of RESULTS
a subset of diabetic nephropathy cases, hypertensive con- Clinical characteristics
trol cases and carotid artery plaque was performed to
The patient and biopsy characteristics are summarizedverify relative immunostaining intensities.
in Table 1. Sixty-four patients met the inclusion criteria.
Patients were classified into two groups, M (N  14)Immunohistochemical scoring
and M (N  50) based on the presence or absence ofGlomerular PPAR was assessed as follows: 0  no
fragmented red blood cells in the mesangium. M andstaining; 1  1 to 2 positive cells/glomerulus; 2  3
M patients showed similar age and racial distribution,to 10 positive cells/glomerulus; 3  
10 positive cells/
although there was a trend for more Caucasian patientsglomerulus. Vascular PPAR was scored as: 0  no
in the M group. It is possible that a larger sample wouldstaining; 1  occasional nuclear staining; 2  50%
reveal a statistically significant increase in Caucasianspositive cells; and 3  50% positive cells per vessel
amongst patients with M lesions. However, the poten-cross section. Tubular PPAR was scored as: 0  no
tial biological significance of this trend remains undeter-staining; 1  weak, very focal 10% of tubules; 2 
mined. The M group included more females comparedmild-moderate in 10 to 30% of tubules; and 3moder-
to M (F/M 2.5 vs. 0.5, P  0.05). In three of the fiveate-severe in 
30% tubules.
M patients in whom laboratory screening tests wereGlomerular PAI-1 was scored as: 0  no staining;
performed, including a complete blood count and chem-110% of each glomerular tuft; 2 10 to 25%; and
istry profile, systemic evidence of hemolysis was evident3  
25% of each tuft. Vascular PAI-1 was scored as:
with RBC changes, elevated LDH, and/or low platelets.0  no staining; 1  occasional positive vessels; 2 
Two of these three patients had low platelets and mild50%; and 3  50% of vessels staining. Tubular PAI-
anisocytosis on peripheral blood smears and one of these1 was scored as: 0  no staining; 1  weak, very focal
three patients had low platelets only. In M, evidence10% of tubules; 2  mild-moderate in 10 to 30% of
of hemolysis was present in only 2 of the 15 patients intubules; and 3  moderate-severe in 
30% tubules.
whom this data was available; one patient had elevated
Statistical analysis LDH enzyme and the other had peripheral blood schisto-
cytes. The indications stated for renal biopsies in ourResults are expressed as mean  standard deviation
study were increased serum creatinine and proteinuria,(SD). Comparisons were made using unpaired t test with
nephrotic range proteinuria, unusual time course for pro-Bonferroni correction for multiple comparisons, or chi-
teinuria/renal dysfunction, hematuria with proteinuriasquare test as appropriate. Morphologic findings were
and/or increased serum creatinine, and rarely other labo-compared by the Mann-Whitney U test. Statistical sig-
nificance was set at P  0.05. ratory abnormalities (Table 1). Thus, the majority of
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Fig. 1. Diabetic nephropathy lesions of fragmented red
blood cells (RBCs). (A) Glomerulus with diabetic glomer-
ulosclerosis and Kimmelstiel-Wilson nodules in a M pa-
tient (periodic acid-Schiff stain, 	400). (B) Glomerulus
with fragmented red blood cells (arrow) in mesangium in
typical M patient (hematoxylin and eosin stain, 	400).
(C) PAI-1 immunostaining in M patient in non-lesional
Kimmelstiel-Wilson nodules. (D) Fragmented RBCs in
M localized exclusively to Kimmelstiel-Wilson nodules
and these lesional areas had marked increase in PAI-1
staining (C and D, anti-PAI-1 immunostaining, 	400).
Fig. 4. Peroxisome proliferator-actived receptor- (PPAR) and macrophage staining. (A) There was no staining for PPAR in M cases in the
lesional areas with RBC fragments (arrow) (anti-PPAR immunostaining 	400). (B) Mesangial cells and parietal epithelial cells showed PPAR
positivity in non-lesional nodules (arrowheads). Occasional visceral epithelial cells were also positive (not shown here). Glomerular macrophages
(red, CD 68, arrow) did not express PPAR (anti-PPAR/CD68 immunostaining, 	400).
patients had renal biopsies for proteinuria and/or ele-
vated serum creatinine and/or hematuria. Proteinuria
was more severe in M patients versus M (9.9  13.6
vs. 4.0 2.8 g/24 h, P 0.05), although serum creatinine
was not different between groups.
Renal lesions
M was present in 21.9% (14/64) of these biopsied
DN patients (Fig. 1 A, B). The M lesions were char-
Fig. 3. Plasminogen activator inhibitor (PAI-1) staining was intense
in carotid artery plaque, especially in macrophages (A), and in sclerotic
glomeruli in hypertensive nephrosclerosis (B), with more focal staining
in diabetic nephropathy (C ) in mesangial cells, visceral and parietal
epithelial cells (anti–PAI-1 immunostaining, 	400).
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1.5  0.8, P  0.05). These lesional nodules also had
numerically higher PAI-1 staining than Kimmelstiel-Wil-
son nodules in M biopsies (K-W nodules in M 1.7 
1.0). Vascular PAI-1 scoring was increased similarly in
DN with or without RBC fragments compared to normal
control (M 1.3  0.9, M 1.5  0.9, both P  0.05 vs.
normal control 0.6  0.9). Tubular PAI-1 score in DN
was increased numerically albeit not significantly (con-
trol 0.8  0.5, M 1.1  0.7, M 1.6  0.5). Positive
control samples obtained from three adult patients with
hypertensive nephrosclerosis showed, as expected, in-
creased glomerular (2.3  0.6), vascular (2.7  0.6) and
tubular staining (2.3  0.7) compared to normal (P 
0.05). Concurrent staining of hypertensive cases and DN
cases verified the relative intensities of PAI-1 immuno-
staining (Fig. 3).
PPAR immunostaining
Glomerular PPAR immunostaining was increased in
DN compared to normal control (M 2.0  1.1, MFig. 2. Fragmented red blood cell (arrowhead) surrounded by halo is
embedded in an area of rarefied mesangium (mesangiolysis) (transmis- 2.6  0.7, both P  0.05 vs. normal control 0.5  0.5).
sion EM, 	11250). PPAR was increased in sclerotic glomeruli with expres-
sion in mesangial, parietal and visceral epithelial cells
(Fig. 4B). There was no PPAR staining in the lesional
areas in M (Fig. 4A).acterized by glomeruli with fragmented red blood cells,
Vascular PPAR in DN was variable and was increasedand localized exclusively in the mesangium of Kimmel-
numerically albeit not significantly (normal control 0.2stiel-Wilson nodules. These lesions were present in 10.2
0.4, M 1.3  0.9, M 1.3  0.8). Tubular PPAR in2.1% of glomeruli in affected biopsies. M patients had
DN was increased numerically albeit not significantlymore extensive nodular glomerulosclerosis (63.3 vs.
(control 1.1 0.4, M 1.9 0.6, M 1.8 0.8). Positive30.6%, P  0.05) and more extensive lamellation than
control samples of hypertensive nephrosclerosis, as ex-M (100 vs. 72.4%, P  0.05). Although it is clear that
pected, showed marked increase of glomerular (2.7 single section analysis overestimates detection of large
0.5), vascular (2.3  0.6) and tubular PPAR (2.4 0.7)nodules, this bias holds true for both M and M cases,
compared to normal.and the relative frequency analysis comparing the two
Double immunostaining for both macrophages andcategories is thus valid.
PPAR demonstrated that glomerular macrophages didBy electron microscopy, mesangiolysis was character-
not express PPAR, although resident glomerular cellsized by rarefied mesangium with cell debris, and was pres-
(including visceral, parietal epithelial cells and mesangialent in 4 of 49 M cases and 2 of 12 M cases. In both
cells) did express PPAR. Interstitial CD68 positive ma-of these two cases of M, we were able to demonstrate
crophages were present in 3 of 12 of M and 14 of 39
RBC fragmentation and mesangiolysis in Kimmelstiel-
of M biopsies, and did express PPAR. Macrophages
Wilson nodules by electron microscopy (Fig. 2).
in human carotid artery plaque, stained as positive con-
trol, were identified by CD68 positivity and also werePAI-1 immunostaining
PPAR positive.
Overall glomerular PAI-1 immunostaining was in-
creased similarly in M and M biopsies when com-
DISCUSSIONpared to normal control (M 1.3  1.0, M 1.8  1.3,
both P 0.05 vs. normal control 0.2 0.4). PAI-1 stain- We hypothesized that mesangial RBC fragments are
ing was present in mesangial cells, visceral and parietal the consequence of microvascular injury and linked to
epithelial cells in DN (Fig. 1 C, D). However, within activation of the fibrinolytic/proteolytic system and PAI-1.
M cases there was marked heterogeneity of PAI-1 ex- Our findings support both of these hypotheses.
pression. Glomerular PAI-1 staining was significantly Vascular lesions such as thrombosis and sclerosis are
increased in Kimmelstiel-Wilson nodules with RBC frag- postulated to be the sequelae of endothelial injury, which
ments compared to Kimmelstiel-Wilson nodules without occurs in many diseases including atherosclerosis, vascu-
lar damage, diabetes mellitus, and thrombotic microan-RBC fragments in these M biopsies (2.6  0.5 vs.
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giopathies [24–29]. Progressive glomerulosclerosis after phages in DN, contrasting with renal interstitial and con-
endothelial injury is hypothesized to reflect an imbalance trol case carotid artery macrophages that were PPAR
between thrombotic/fibrinolytic and sclerotic/antiprote- positive. Monocytes and macrophages play important
olytic activities. In vivo animal data show the presence of roles in immune and nonimmune chronic sclerosing renal
PAI-1 in settings of vascular injury [30]. PAI-1 also is ex- disease [43–45]. Activated macrophages are rich sources
pressed in vitro in many cells, including endothelial and of growth factors, cytokines, vasoactive substances, reac-
glomerular visceral epithelial cells [31–33]. PAI-1 has been tive oxygen species, and proteolytic enzymes [46]. We
recognized to play a role in ECM metabolism by inhib- hypothesize that there is a phenotypic difference of mac-
iting its degradation [4]. PAI-1 is increased in conditions rophages in glomerular versus vascular sclerosis. Macro-
associated with thrombosis, including hemolytic uremic phages in human atherosclerotic carotid artery plaques
syndrome. Elevated plasma PAI-1 in hemolytic uremic did express PPAR and are thought to promote foam
syndrome correlated with progression of thrombosis to cell transformation [17]. PPAR agonists have been
sclerosis long-term [4]. Elevated plasma PAI-1 also is shown to ameliorate hyperlipidemia, improve insulin
associated with increased risk of cardiovascular disease sensitivity and decrease sclerosis in rat diabetic models
and recurrence of myocardial infarction [4, 34]. [17, 21]. However, these results on sclerosis could be just
Many studies have shown that the plasma level of consequent to improved diabetic control. Our in vivo
PAI-1 is increased in diabetes [11, 12, 35–37]. Elevated animal data suggest that glomerular intrinsic cells are
plasma PAI-1 is associated with diabetic complications, targets of PPAR agonists and that activation of PPAR
such as microalbuminuria, neuropathy, retinopathy and protects against glomerular and vascular sclerosis even
lower extremity arterial diseases suggesting that circu- in a nondiabetic model of injury [23]. This action of
lating PAI-1 may correlate with increased vascular injury PPAR was linked to decreased macrophage influx, de-
[35–37]. Our study is the first demonstration, to our creased PAI-1 and altered cell turnover. PPAR ligands
knowledge, of increased local PAI-1 in DN: PAI-1 was can inhibit injury in a mouse model of colitis with PPAR
overexpressed in areas of severe lesions, that is, Kimmel- expression primarily in the colonic epithelium, even in the
stiel-Wilson nodules, and was even higher in nodules presence of intense inflammation, thus supporting that
with active microvascular injury evidenced by RBC frag- PPARmodifies consequences of inflammation [47]. We
ments. Our previous studies have shown tight correlation speculate that increased glomerular PPAR in human
of PAI-1 mRNA by in situ hybridization and PAI-1
DN may be a counter-regulatory mechanism in response
protein by immunostaining. PAI-1 is rapidly released
to glomerular sclerosis, and that this local PPAR ex-after synthesis and has a short half-life. We therefore
pression may activate antiinflammatory and/or antiscle-interpret the immunostaining to represent local PAI-1
rotic mechanisms. We also speculate that the increasedprotein, originating from local synthesis rather than trap-
PPAR might have even contributed to dampen the up-ping, and speculate that the even higher PAI-1 in hyper-
regulation of PAI-1.tensive nephrosclerosis cases may relate to more severe
We further conclude that mesangial RBC fragmentsvascular injury and endothelial dysfunction and hyper-
are indicative of microvascular injury in DN and are as-tension in those cases.
sociated with worse proteinuria, and thus this lesion couldIntraglomerular RBC fragmentation is a novel injury
possibly imply a worse prognosis. The possible patho-pattern that has not been previously described in DN.
genic mechanisms of this lesion involve the fibrinolytic/RBC fragmentation is a lesion associated with throm-
proteolytic system and local activation of PAI-1.botic microangiopathy and mesangiolysis. Mesangiolysis
is an injurious process manifest by attenuation or dissolu-
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